Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran.
Department of Internal Medicine, University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia.
Crit Rev Food Sci Nutr. 2021;61(2):325-336. doi: 10.1080/10408398.2020.1731678. Epub 2020 Feb 23.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protease which increases the lysosomal degradation of low density lipoprotein receptor (LDLR) resulting in elevated serum LDL-cholesterol levels. Elevated LDL-cholesterol is the main risk factor for cardiovascular disease (CVD). Antibodies to PCSK9 decrease LDL-cholesterol. Recent studies have suggested a direct relationship between PCSK9 and inflammation and the potential inhibitory effects of anti-inflammatory agents against this enzyme. Nutraceuticals are natural compounds, which have numerous anti-inflammatory and lipid-lowering effects. In this review we focus on anti-inflammatory substances and nutraceuticals, which are beneficial in treatment of dyslipidemia. We also reviewed the recent findings concerning the role of PCSK9 as the main target for molecular mechanisms of these substances.
前蛋白转化酶枯草溶菌素 9（PCSK9）是一种蛋白酶，可增加低密度脂蛋白受体（LDLR）的溶酶体降解，导致血清 LDL-胆固醇水平升高。升高的 LDL-胆固醇是心血管疾病（CVD）的主要危险因素。针对 PCSK9 的抗体可降低 LDL-胆固醇。最近的研究表明，PCSK9 与炎症之间存在直接关系，以及抗炎药物对这种酶的潜在抑制作用。营养保健品是具有多种抗炎和降血脂作用的天然化合物。在这篇综述中，我们重点关注抗炎物质和营养保健品，它们对治疗血脂异常有益。我们还回顾了最近关于 PCSK9 作为这些物质的分子机制的主要靶点的研究结果。
